Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN022150 vs Chemotherapy in Advanced Pancreatic Cancer With KRAS G12D Mutation
NCT07689539Phase 3Not yet recruiting
- Sponsor
- Jiangxi Kvvit Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Jul 2028
01
Overview
A Phase 3 trial of DN-022150 in pancreatic cancer (PC), sponsored by Jiangxi Kvvit Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
DN-022150
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07689539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689539.